All assets necessary to run the Holter, cardiac event and mobile telemetry service lines are transferring to
BMS Chief Executive Officer,
About Biomedical Systems
Biomedical Systems is a worldwide provider of centralized clinical trial services and cardiac monitoring solutions. Since 1975, Biomedical Systems has provided cardiologists, clinics, and hospitals with ECG monitoring solutions including Holter monitoring, cardiac event monitoring, and 12 lead ECG services. Clinical trial services include cardiac safety, pulmonary function, scientific affairs, medical imaging, neurophysiology, digital pathology, and electronic patient reported outcomes.
This document includes certain forward-looking statements within the meaning of the "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our expectations regarding the success of the BMS transaction and related effect on the Company's operations. These statements may be identified by words such as "expect," "anticipate," "estimate," "intend," "plan," "believe," "promises" and other words and terms of similar meaning. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of these expectations, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, effects of changes in health care legislation, effectiveness of our cost savings initiatives, relationships with our government and commercial payors, changes to insurance coverage and reimbursement levels for our products, the success of our sales and marketing initiatives, our ability to attract and retain talented executive management and sales personnel, our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business, the commercialization of new products, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development, changes in governmental regulations and legislation, the continued consolidation of payors, acceptance of our new products and services, patent protection, adverse regulatory action, litigation success, our ability to successfully create a new holding company structure and to anticipate the benefits of such structure. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the
BioTelemetry, Inc. Heather C. GetzInvestor Relations 800-908-7103 firstname.lastname@example.org